What is the share price of Fredun Pharmaceuticals Ltd (FREDUN) today?
The share price of FREDUN as on 8th July 2025 is ₹820. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Fredun Pharmaceuticals Ltd (FREDUN) share?
The past returns of Fredun Pharmaceuticals Ltd (FREDUN) share are- Past 1 week: -3.65%
- Past 1 month: 11.52%
- Past 3 months: 23.28%
- Past 6 months: 16.36%
- Past 1 year: -2.80%
- Past 3 years: -3.19%
- Past 5 years: 357.46%
What are the peers or stocks similar to Fredun Pharmaceuticals Ltd (FREDUN)?
The peers or stocks similar to Fredun Pharmaceuticals Ltd (FREDUN) include:What is the dividend yield % of Fredun Pharmaceuticals Ltd (FREDUN) share?
The current dividend yield of Fredun Pharmaceuticals Ltd (FREDUN) is 0.09.What is the market cap of Fredun Pharmaceuticals Ltd (FREDUN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Fredun Pharmaceuticals Ltd (FREDUN) is ₹384.39 Cr as of 8th July 2025.What is the 52 week high and low of Fredun Pharmaceuticals Ltd (FREDUN) share?
The 52-week high of Fredun Pharmaceuticals Ltd (FREDUN) is ₹904 and the 52-week low is ₹635.What is the PE and PB ratio of Fredun Pharmaceuticals Ltd (FREDUN) stock?
The P/E (price-to-earnings) ratio of Fredun Pharmaceuticals Ltd (FREDUN) is 19.47. The P/B (price-to-book) ratio is 3.16.Which sector does Fredun Pharmaceuticals Ltd (FREDUN) belong to?
Fredun Pharmaceuticals Ltd (FREDUN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Fredun Pharmaceuticals Ltd (FREDUN) shares?
You can directly buy Fredun Pharmaceuticals Ltd (FREDUN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Fredun Pharmaceuticals Ltd
FREDUN Share Price
820.000.72% (+5.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
FREDUN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
FREDUN Performance & Key Metrics
FREDUN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 3.16 | 0.09% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.97 | 6.46 | 0.64% |
FREDUN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
FREDUN Company Profile
Fredun Pharmaceuticals Ltd. is a pharmaceutical company engaged in the manufacturing and sale of pharmaceutical formulations. The Company’s products include I V fluids, disposable syringes, infusion sets, surgical gloves and cottons etc.
SUNPHARMA
PE Ratio
36.88
36.88
1Y Return
7.46%
7.46%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.14
23.14
1Y Return
0.20%
0.20%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.36
59.36
1Y Return
15.25%
15.25%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
19.28
19.28
1Y Return
1.75%
1.75%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.21
22.21
1Y Return
15.08%
15.08%
Buy Reco %
44.44
44.44
FREDUN Forecast
FREDUN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
FREDUN
FREDUN
Income
Balance Sheet
Cash Flow
Annual Normal View
FREDUN Income Statement
FREDUN Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 58.61 | 59.71 | 97.40 | 113.29 | 135.29 | 226.09 | 276.50 | 349.08 | 456.27 | — | ||||||||||
Raw Materials | 34.20 | 42.98 | 65.96 | 86.12 | 100.60 | 176.45 | 245.57 | 282.42 | 401.36 | — | ||||||||||
| Power & Fuel Cost | 1.64 | 1.65 | 3.10 | 3.21 | 3.32 | 3.68 | 3.17 | 4.03 | ||||||||||||
| Employee Cost | 4.92 | 5.19 | 8.04 | 8.95 | 8.66 | 10.66 | 11.54 | 12.50 | ||||||||||||
| Selling & Administrative Expenses | 6.57 | 5.66 | 9.83 | 6.43 | 7.80 | 12.76 | 14.55 | 20.77 | ||||||||||||
| Operating & Other expenses | 6.04 | -1.64 | -0.14 | -0.27 | 5.33 | 7.04 | -27.93 | -9.55 | ||||||||||||
EBITDA | 5.24 | 5.87 | 10.61 | 8.85 | 9.58 | 15.50 | 29.60 | 38.91 | 54.91 | — | ||||||||||
| Depreciation/Amortization | 1.14 | 1.29 | 1.33 | 1.88 | 2.00 | 2.16 | 2.81 | 3.80 | 5.04 | — | ||||||||||
| PBIT | 4.10 | 4.58 | 9.28 | 6.97 | 7.58 | 13.34 | 26.79 | 35.11 | 49.87 | — | ||||||||||
| Interest & Other Items | 1.87 | 1.94 | 3.13 | 4.48 | 4.37 | 4.74 | 9.28 | 13.65 | 22.38 | — | ||||||||||
| PBT | 2.23 | 2.64 | 6.15 | 2.49 | 3.21 | 8.60 | 17.51 | 21.46 | 27.49 | — | ||||||||||
| Taxes & Other Items | 0.80 | 0.89 | 1.70 | 0.59 | 1.20 | 2.26 | 6.70 | 5.83 | 7.75 | — | ||||||||||
| Net Income | 1.43 | 1.75 | 4.45 | 1.90 | 2.01 | 6.34 | 10.81 | 15.63 | 19.74 | — | ||||||||||
| EPS | 5.97 | 6.01 | 12.00 | 4.76 | 5.04 | 15.06 | 24.12 | 33.86 | 44.83 | — | ||||||||||
| DPS | 0.60 | 0.60 | 0.65 | 0.66 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | — | ||||||||||
| Payout ratio | 0.10 | 0.10 | 0.05 | 0.14 | 0.14 | 0.05 | 0.03 | 0.02 | 0.02 | — |
FREDUN Company Updates
FREDUN Stock Peers
FREDUN Past Performance & Peer Comparison
FREDUN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Fredun Pharmaceuticals Ltd | 19.47 | 3.16 | 0.09% |
| Sun Pharmaceutical Industries Ltd | 36.88 | 5.56 | — |
| Cipla Ltd | 23.14 | 3.90 | 1.06% |
| Torrent Pharmaceuticals Ltd | 59.36 | 14.95 | — |
FREDUN Stock Price Comparison
Compare FREDUN with any stock or ETFCompare FREDUN with any stock or ETF
FREDUN
FREDUN Holdings
FREDUN Shareholdings
FREDUN Promoter Holdings Trend
FREDUN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
FREDUN Institutional Holdings Trend
FREDUN Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.37%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
FREDUN Shareholding Pattern
FREDUN Shareholding Pattern
FREDUN Shareholding History
FREDUN Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing FREDUN stock
smallcases containing FREDUN stock
Looks like this stock is not in any smallcase yet.
FREDUN Events
FREDUN Events
FREDUN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
FREDUN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.09%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.86 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
FREDUN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
FREDUN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.09%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.86 every year
FREDUN Upcoming Dividends
FREDUN Upcoming Dividends
No upcoming dividends are available
FREDUN Past Dividends
FREDUN Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹0.70
Dividend/Share
₹0.70
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹0.70
Dividend/Share
₹0.70
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 16, 2021
Final
Final | Div/Share: ₹0.70
Dividend/Share
₹0.70
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateSep 16, 2019
Final
Final | Div/Share: ₹0.65
Dividend/Share
₹0.65
Ex DateEx Date
Sep 16, 2019
Cash Dividend
Ex DateEx DateSep 18, 2018
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 18, 2018
FREDUN Stock News & Opinions
FREDUN Stock News & Opinions
Articles & Videos
Earnings
Fredun Pharmaceuticals standalone net profit rises 39.72% in the March 2025 quarter
Net profit of Fredun Pharmaceuticals rose 39.72% to Rs 7.07 crore in the quarter ended March 2025 as against Rs 5.06 crore during the previous quarter ended March 2024. Sales rose 41.15% to Rs 165.44 crore in the quarter ended March 2025 as against Rs 117.21 crore during the previous quarter ended March 2024. For the full year,net profit rose 33.23% to Rs 20.81 crore in the year ended March 2025 as against Rs 15.62 crore during the previous year ended March 2024. Sales rose 30.33% to Rs 451.71 crore in the year ended March 2025 as against Rs 346.58 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales165.44117.21 41 451.71346.58 30 OPM %10.549.53 -12.2011.22 - PBDT9.296.80 37 32.7225.25 30 PBT8.045.84 38 28.2721.45 32 NP7.075.06 40 20.8115.62 33 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Board of Fredun Pharmaceuticals recommends final dividend
Fredun Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.7 per equity Share (i.e. 7%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Fredun Pharmaceuticals declare Quarterly Result
Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Fredun wins order from Tamil Nadu Medical Services Corporation
Fredun Pharmaceuticals has been awarded a significant tender by the Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicines. The total value of the tender ranges between Rs. 15-18 crore. The supply of these goods is set to commence within the first quarter of FY26 and will extend over a period of 14 months. Commenting on the Development, Fredun Medhora, Managing Director, said: 'We are thrilled to have been awarded this tender by TNMSC. This achievement reflects our ongoing efforts to deliver quality healthcare solutions and our commitment to serving the needs of the public health sector. We look forward to a successful collaboration with TNMSC and to making a positive impact on the healthcare landscape in Tamil Nadu.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Fredun Pharmaceuticals announces its foray into large animal veterinary segment
Fredun Pharmaceuticals announced its foray into the large animal veterinary segment, under the FREOSSI Large Animals brand with the launch of targeted products Freossi Tone+ and Freossi Power. FREOSSI has a strong & existing reputation in companion animal care, hence this will provide a foundation of trust and reliability when expanding into large animal products. These new products have scientific & clinical evidence and are developed with the expertise of veterinary professionals in animal health. They specifically are designed to address key health challenges faced by livestock owners including lactation issues, quality of milk, joint stiffness, and mobility concerns. Commenting on the Development, Fredun Medhora, Managing Director, said: 'Our foray into the large animal healthcare space is a strategic step in expanding Fredun Pharma's presence in veterinary healthcare, while reinforcing our commitment to innovation and quality. With Freossi Tone + and Freossi Power, we are addressing key challenges faced by livestock owners while promoting the overall advancement of animal health. This marks an important milestone as we work towards offering specialized solutions across the broader veterinary spectrum.' Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Fredun Pharmaceuticals standalone net profit rises 26.30% in the December 2024 quarter
Net profit of Fredun Pharmaceuticals rose 26.30% to Rs 5.33 crore in the quarter ended December 2024 as against Rs 4.22 crore during the previous quarter ended December 2023. Sales rose 17.53% to Rs 101.84 crore in the quarter ended December 2024 as against Rs 86.65 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales101.8486.65 18 OPM %12.9812.14 - PBDT8.226.75 22 PBT7.135.76 24 NP5.334.22 26 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Fredun Pharmaceuticals to table results
Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Fredun Pharmaceuticals standalone net profit rises 8.38% in the September 2024 quarter
Net profit of Fredun Pharmaceuticals rose 8.38% to Rs 4.27 crore in the quarter ended September 2024 as against Rs 3.94 crore during the previous quarter ended September 2023. Sales rose 31.19% to Rs 106.89 crore in the quarter ended September 2024 as against Rs 81.48 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales106.8981.48 31 OPM %13.0411.79 - PBDT8.636.71 29 PBT7.575.77 31 NP4.273.94 8 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Fredun Pharmaceuticals to discuss results
Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Fredun Pharmaceuticals to hold board meeting
Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 3 October 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 32.13%, vs industry avg of 10.22%
Over the last 5 years, market share increased from 0.05% to 0.11%
Over the last 5 years, net income has grown at a yearly rate of 59.71%, vs industry avg of 20.11%